NCT03256981 2023-12-26
HALT
Institute of Cancer Research, United Kingdom
Phase 2/3 Unknown
Clinical Trials
29 trialsNCT06108726 2023-10-31
A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
Northern Jiangsu People's Hospital
Phase 2 Unknown
NCT06020352 2023-08-31
The Efficacy and Safety of KN046 Combined With Axitinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2/3 Unknown
NCT04811001 2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT05651269 2022-12-15
Milciclib in Combination With Gemcitabine in Advanced NSCLC
Tiziana Life Sciences LTD
Phase 2 Unknown
NCT05605613 2022-11-09
PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial
The First Affiliated Hospital of Zhengzhou University
Phase 2/3 Unknown
NCT05332574 2022-08-05
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
Genor Biopharma Co., Ltd.
Phase 1/2 Unknown
NCT05117658 2022-08-04
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT05387109 2022-05-24
pcwaintrl
Tang-Du Hospital
Phase 4 Unknown
NCT05209256 2022-01-26
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2/3 Unknown
NCT05065398 2022-01-21
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
Shanghai Henlius Biotech
Phase 2 Unknown
NCT05165355 2022-01-18
ATHEM
Tongji University
Phase 2 Unknown
NCT03986528 2021-02-23
Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 4 Unknown
NCT04390984 2021-01-11
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT04506242 2020-09-09
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT04164745 2019-11-15
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
NCT03799601 2019-01-10
ALTER-L013
Tongji Hospital
Phase 4 Unknown
NCT03606070 2019-01-04
IMAHTEP
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Unknown
NCT03656393 2018-09-04
RCTACSCNSCLC
Shenzhen People's Hospital
Phase 3 Unknown
NCT03416231 2018-01-31
Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
Affiliated Hospital of North Sichuan Medical College
Phase 2 Unknown
NCT03269162 2017-09-14
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Shanghai University of Traditional Chinese Medicine
Phase 3 Unknown
NCT02404675 2017-07-28
INCREASE
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT02778893 2016-05-20
Conmana Combined With Thalidomide to Treat NSCLC
Henan Provincial People's Hospital
Phase 4 Unknown
NCT02631460 2015-12-16
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
Sun Yat-sen University
Phase 2 Unknown
NCT02387086 2015-03-12
Gefitinib Combined With Thalidomide to Treat NSCLC
Shaanxi Provincial People's Hospital
Phase 2/3 Unknown
NCT02140333 2015-02-12
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Unknown
NCT02272127 2014-10-22
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT01932229 2013-08-30
An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
Sheba Medical Center
Phase 2 Unknown